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Abstract 
Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. 
Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of 
combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could 
be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination.
Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in 
renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial 
of lithium versus placebo in patients with HIV-associated neurocognitive impairment.
Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with 
a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with 
an eGFR <60 mL/min and treated with medications predisposing to lithium toxicity. We reviewed participants weekly 
for the first month for adverse events followed by 4 weekly visits for renal function assessment, adverse event moni-
toring and adherence. Lithium dose was titrated to achieve the maintenance target plasma concentration of between 
0.6 and 1.0 mmol/L. Sham lithium concentrations were generated for participants receiving placebo.
Results: We included 23 participants allocated to the lithium arm and 30 participants allocated to the placebo arm. 
Baseline characteristics were not statistically different with a mean age of 37.7 and 40.8 years, a median time on ART of 
33 and 40 months and an eGFR of 139.3 and 131.0 mL/min in the lithium and placebo arms respectively. There was no 
statistical significant difference in the reduction in eGFR or increase in potassium between the two arms during the 
24 weeks.
Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in 
increased nephrotoxicity.
Trial registration The study was registered on the Pan African Clinical Trials Registry (PACTR) with the identifier number 
PACTR201310000635418. Registered 11 October 2013 before the first participant was enrolled
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Background
The prevalence of bipolar disorder in human immuno-
deficiency virus (HIV)-infected patients is 4–5 times 
higher than the general population [1, 2]. The most 
effective mood stabiliser is lithium while the nucleotide 
reverse transcriptase inhibitor tenofovir disoproxil fuma-
rate (TDF) is frequently used as part of combination 
antiretroviral therapy (ART) [3]. Both TDF and lithium 
are associated with renal tubular toxicity, which could 
be additive [4, 5]. Furthermore, a TDF-lithium pharma-
cokinetic interaction may occur at renal transporters. 
TDF is eliminated via proximal tubular secretion and 
renal toxicity is thought to be related to accumulation 
of intracellular tenofovir in the proximal tubular cell [6]. 
Intracellular TDF inhibits mitochondrial deoxyribonu-
cleic acid (DNA) polymerase gamma with DNA deple-
tion and oxidative respiratory chain dysfunction [7]. 
Mitochondrial dysfunction impairs tubular reabsorption 
of ions and molecules causing a Fanconi-like syndrome, 
or may lead to cell apoptosis and acute tubular necrosis 
[7]. TDF is a substrate of a number of transporters at the 
proximal renal tubule. The organic anion transporter-1 
(OATP-1) transports TDF intracellularly while the multi-
drug resistance protein 4 (MRP-4) mediates active secre-
tion from the tubular cell [8]. In rats lithium impairs 
OATP-1 function, which may protect against TDF renal 
toxicity [9]. Twenty to eighty seven percent of lithium 
treated patients develop a reduction in urinary concen-
trating ability within weeks after starting treatment [10]. 
Lithium-induced nephrogenic diabetes insipidus (NDI) is 
thought to be caused by downregulation of intracellular 
calcium signalling with inhibition of glycogen synthase 
kinase-3-beta (GSK-3-ß), resulting in a number of down-
stream effects including decreased aquaporin-2 expres-
sion [11]. Recently it was shown that MRP-1 expression 
is regulated by GSK-3-β, suggesting that lithium may 
decrease MRP expression and predispose to TDF renal 
toxicity [12]. The proximal tubule as a common site for 
TDF and lithium renal toxicity may further contribute 
to renal toxicity. Lithium-induced renal toxicity may 
involve any segment of the nephron or kidney although 
the distal tubule seems to be involved in NDI [13]. There 
is currently no published data on the renal safety of con-
comitant TDF and lithium.
We previously published the results of a 24 week ran-
domised placebo-controlled trial to study lithium as an 
adjunctive pharmacotherapy in patients with moderate 
to severe HIV-associated neurocognitive impairment 
[14]. In this study we report changes in the estimated glo-
merular filtration rate (eGFR) using the modification of 
diet in renal disease (MDRD) formula as well as changes 
in potassium in participants who received ART including 
TDF who were randomised to lithium or placebo.
Methods
Our methodology has been previously published, 
but in brief we included HIV-infected adults (≥18 
and ≤70 years), established on ART for at least 6 months 
with a suppressed viral load (HIV RNA  <400 copies/
mL) with cognitive impairment attending public sector 
ART clinics in Cape Town, South Africa [14]. We dosed 
lithium carbonate 250  mg tablets (Camcolit®, manufac-
tured by Norgine) and matching placebo (manufactured 
by Norgine). We excluded participants who used medi-
cations that may predispose to lithium toxicity (diuretics, 
angiotensin converting enzyme inhibitors or angioten-
sin receptor blockers and non-steroidal anti-inflamma-
tory medicines), participants with an eGFR of less than 
60 mL/min and dehydrated participants with diarrhoea. 
We reviewed participants weekly for first month followed 
by 4 weekly visits for adverse events and adherence. After 
screening and study drug initiation, we repeated renal 
function (sodium, potassium, urea and creatinine) at 
weeks 4, 8, 12, 16, 20 and 24. Some participants switched 
treatment to TDF during the study period, and for this 
analysis we only included patients who received TDF 
for the full 24  weeks. Lithium dose was titrated assum-
ing linear pharmacokinetics to achieve the maintenance 
target plasma concentration of lithium in patients with 
bipolar mood disorder of between 0.6 and 1.0  mmol/L. 
Sham lithium concentrations were generated for par-
ticipants receiving placebo by the study statistician who 
was unblinded to treatment allocation. After each visit 
an investigator not directly responsible for participant 
follow-ups received a log with the participant number, 
blinded lithium concentration from the study statistician 
(real or sham), current study drug dose and any adverse 
events noted by other investigators. Based on the infor-
mation the investigator recommended lithium and sham 
dose adjustments for implementation.
Results
We included 53 participants in this analysis with 23 par-
ticipants allocated to the lithium arm and 30 participants 
allocated to the placebo arm. Baseline characteristics 
between the 2 arms were similar and are described in 
Table 1. Adherence in both treatment arms were similar 
and reported previously [14]. The proportion of patients 
with lithium concentrations in the therapeutic range 
are presented in Fig.  1. Three participants allocated to 
the lithium arm developed symptoms of NDI (polyuria) 
which resolved on dose reduction (p = 0.042 compared 
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to placebo arm). No participant allocated to the placebo 
arm developed symptoms of NDI. Change in eGFR, cre-
atinine and potassium were similar between the 2 arms 
(see Figs. 2, 3, 4). There was no statistical significant dif-
ference between the two arms in the proportion of par-
ticipants who had a reduction in eGFR (see Table  2). 
There was no statistically significant difference in the 
eGFR slope between the 2 treatment arms (see Fig. 2a) (p 
value = 0.06) when using linear regression.
Table 1 Baseline characteristics
eGFR estimated glomerular filtration rate, MDRD modification of diet in renal 
disease formula
a Mean and standard deviation
b Median and interquartile range
c t-test (2 samples)
d Wilcoxon sum rank
e Fisher’s exact test
Baseline  
characteristic
Lithium  
(n = 23)
Placebo  
(n = 30)
p value
Gender
 Male n = 1 (4%) n = 4 (13%) 0.374e
 Female n = 22 (96%) n = 26 (87%)
Age 37.7 ± 8.1a years 40.8 ± 8.54a years 0.186c
Weight 68.5 ± 16.2a kg 71.2 ± 12.7a kg 0.493c
Months on ART 33 (12–56)b months 40 (26–68)b months 0.262d
Renal function
 Creatinine 58 (49–62)b µmol/L 58.5 (50–68)b 
µmol/L
0.404d
 eGFR MDRD 139.3 (118.1–159.7)b 
mL/min
131.0 (110.9–156.9)b 
mL/min
0.572d
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Fig. 1 The graph shows the mean change in lithium concentrations. 
The bars indicate median and interquartile range change in lithium 
concentrations over the 24 weeks in the lithium and placebo arms 
respectively. Sham lithium concentrations were generated for the 
placebo arm. The broken line indicates the target therapeutic range of 
0.6–1.0 mmol/L
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Fig. 2 a The graph shows the mean estimated glomerular filtration 
rate (eGFR) as calculated using the modification of diet in renal 
disease (MDRD). The bars indicate median and interquartile range 
change in eGFR over the 24 weeks in the lithium and placebo arms 
respectively. b Scatter plot of estimated glomerular filtration rate 
(eGFR) as calculated using the modification of diet in renal disease 
(MDRD) over the 24 weeks in the lithium and placebo arms respec-
tively. The solid lines indicate the linear regression lines for the lithium 
and placebo arms respectively. Treatment allocation did not have a 
statistically significant effect on eGFR (p value 0.06)
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Fig. 3 The graph shows the mean change in creatinine (µmol/L). The 
bars indicate median and interquartile range of creatinine over the 
24 weeks in the lithium and placebo arms respectively
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Discussion
We reported the renal safety of lithium co-administered 
with TDF as part of a 24 week randomised placebo-con-
trolled trial. To the best of our knowledge we described 
the first safety data of co-administered lithium with TDF. 
We found that lithium and TDF co-administration did 
not increase the risk of renal impairment in HIV-infected 
patients with neurocognitive impairment and preserved 
renal function over a 24-week period.
NDI is a well-recognised early side effect of lithium 
administration. Lithium causes dysregulation of the 
aquaporin-2 water channels in the collecting ducts 
with impaired pro-urine concentration ability [13, 15]. 
Three patients in the lithium arm developed NDI which 
resolved with a lithium dose reduction. Lithium-induced 
nephrotoxicity has been long recognised, but the extent 
and risk factors required to frame a risk-benefit profile 
for patients has been much debated [16]. A recent pop-
ulation-based study in psychiatric patients with lithium 
exposure found that monthly eGFR decline was similar 
in the lithium and reference group after adjusting for co-
morbidities, concomitant medication and episodes of 
lithium toxicity [17]. Our findings in a young cohort with 
no lithium toxicity episodes and limited treatment dura-
tion echo these findings.
Our study has several limitations. First, we reported 
on the safety of lithium dosed with TDF in a randomised 
placebo-controlled trial that was not powered for this 
endpoint. Second, we followed patients for 24 weeks and 
we can only make inferences about the short-term safety 
of concomitant lithium and TDF administration. Third, 
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Fig. 4 The graph shows the mean change in potassium. The bars 
indicate median and interquartile range change in potassium over 
the 24 weeks in the lithium and placebo arms respectively
Table 2 Estimated glomerular filtration rate change
eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease formula
a Chi-squared test
b One-sided Fisher’s exact test
c Participants did not attend the specific study visit
d Grading according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (Version 2.0 November 2014)
eGFR MDRD changed Treatment arm Week 4 % (n) Week 8 % (n) Week 12 % (n) Week 16 % (n) Week 20 % (n) Week 24 % (n)
Increased Lithium 30.4% (7/23) 39.1% (9/23) 39.1% (9/23) 34.8% (8/23) 39.1% (9/23) 56.5% (13/23)
Placebo 40% (12/30) 50% (15/30) 43.3% (13/30) 33.3% (10/30) 43.3% (13/30) 46.7% (14/30)
p = 0.518a p = 0.621a p = 0.095a p = 0.012a p = 0.095a p = 0.506a
Grade 1
Decreased 0.1% to <10% from 
baseline
Lithium 34.8% (8/23) 13% (3/23) 8.7% (2/23) 26.1% (6/23) 17.4% (4/23) 8.7% (2/23)
Placebo 23.3% (7/30) 16.7% (5/30) 20% (6/30) 23.3% (7/30) 30% (9/30) 20% (6/30)
p = 0.495a p = 0.264b p = 0.229b p = 0.817a p = 0.233b p = 0.229b
Grade 2
Decreased 10 to <30% from 
baseline
Lithium 26.0% (6/23) 26.1% (9/23) 43.5% (10/23) 21.7% (5/23) 34.8% (8/23) 23% (6/23)
Placebo 26.7% (8/30) 13.3% (5/30) 30% (9/30) 33.3% (10/30) 13.3% (4/30) 30% (9/30)
p = 0.971a p = 0.164a p = 0.765a p = 0.484a p = 0.145a p = 0.814b
Grade 3
Decreased ≥30 to <50% from 
baseline
Lithium 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23)
Placebo 0% 0% 3.3% (1/30) 0% 13.3% (4/30) 3.3% (1/30)
p = 0.202b p = 0.202b p = 0.418b p = 0.202b p = 0.493b p = 0.418b
Grade 4
Decreased ≥50% from baseline
Lithium 0% 0% 0% 0% 0% 0%
Placebo 0% 0% 0% 3.3% (1/30) 0% 0%
p = 574b
Creatinine not measuredc Lithium 0% 0% 0% 4.3% (1/23) 0% 0%
Placebo 0% 10% (3/30) 3.3% (1/30) 3.3% (1/30) 0% 0%
p = 0.197b p = 0.574b p = 0.687b
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we may have missed more subtle markers of tubulopa-
thy as we did not measure urine markers of tubulopa-
thy. Fourth, only approximately half of participants had 
therapeutic lithium trough concentrations. We collected 
lithium trough concentrations as soon as participants 
arrived at the study site and despite best efforts, sample 
collection time for some participants was beyond 12  h. 
Last, we excluded patients with renal impairment and 
concomitant medication which may potentiate lithium 
toxicity.
We could not rule out nephrotoxicity of long-term 
concomitant treatment of TDF and lithium and future 
research should focus on the long-term follow-up of 
TDF-treated HIV-infected patients with lithium-treated 
bipolar disorder.
Conclusions
We found that 24-week treatment of HIV-infected 
patients with lithium and TDF, preserved renal func-
tion and no episodes of lithium toxicity did not result in 
increased nephrotoxicity. To the best of our knowledge 
we described the first safety data of co-administered lith-
ium with TDF. Our finding supports the renal safety of 
TDF-based ART in HIV-infected patients with bipolar 
disorder requiring lithium therapy as a mood stabiliser.
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